{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:44:38Z","timestamp":1794037478858,"version":"4.8.0"},"posted":{"date-parts":[[2024,11,3]]},"group-title":"Bioengineering","reference-count":74,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Immunotherapy has shown promise for treating patients with autoimmune diseases or cancer, yet treatment is associated with adverse effects associated with global activation or suppression of T cell immunity. Here, we developed antigen-presenting nanoparticles (APNs) to selectively engineer disease antigen (Ag)-specific T cells by\n                  <jats:italic>in vivo<\/jats:italic>\n                  mRNA delivery. APNs consist of a lipid nanoparticle core functionalized with peptide-major histocompatibility complexes (pMHCs), facilitating antigen-specific T cell transfection through cognate T cell receptor-mediated endocytosis. In mouse models of type 1 diabetes and multiple myeloma, APNs selectively deplete autoreactive T cells leading to durable control of glycemia, and engineer virus-specific T cells with anti-cancer chimeric antigen receptors (CARs), achieving comparable therapeutic outcome as virally transduced\n                  <jats:italic>ex vivo<\/jats:italic>\n                  CAR. Overall, our work supports the use of APNs to engineer disease-relevant T cells\n                  <jats:italic>in vivo<\/jats:italic>\n                  as Ag-specific immunotherapy for autoimmune disorders and cancer.\n                <\/jats:p>","DOI":"10.1101\/2024.10.29.620946","type":"posted-content","created":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T07:50:18Z","timestamp":1730620218000},"source":"Crossref","is-referenced-by-count":6,"title":["Antigen-specific T cell immunotherapy by in vivo mRNA delivery"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2852-161X","authenticated-orcid":false,"given":"Fang-Yi","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0424-7487","authenticated-orcid":false,"given":"Jamison C.","family":"Siebart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching S.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron Silva","family":"Trenkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avanti","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rustin","family":"Harandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Shahrawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshika","family":"Goenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhee","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6255-6755","authenticated-orcid":false,"given":"Gabriel A.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2024110512151066000_2024.10.29.620946v1.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade6967"},{"key":"2024110512151066000_2024.10.29.620946v1.2","doi-asserted-by":"crossref","unstructured":"Hamilton JR , Chen E , Perez BS , Sandoval Espinoza CR , Kang MH , Trinidad M , et al. In vivo human T cell engineering with enveloped delivery vehicles. Nature Biotechnology 2024.","DOI":"10.1038\/s41587-023-02085-z"},{"key":"2024110512151066000_2024.10.29.620946v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19486-2"},{"key":"2024110512151066000_2024.10.29.620946v1.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594"},{"issue":"5","key":"2024110512151066000_2024.10.29.620946v1.5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/d41573-021-00063-1","article-title":"FDA approves first BCMA-targeted CAR-T cell therapy","volume":"20","year":"2021","journal-title":"Nature reviews Drug discovery"},{"key":"2024110512151066000_2024.10.29.620946v1.6","doi-asserted-by":"crossref","unstructured":"Mullard A. FDA approves first TCR-engineered T cell therapy, for rare soft-tissue cancer. Nature reviews Drug discovery 2024.","DOI":"10.1038\/d41573-024-00134-z"},{"key":"2024110512151066000_2024.10.29.620946v1.7","doi-asserted-by":"crossref","unstructured":"Wang S , Du Y , Zhang B , Meng G , Liu Z , Liew SY , et al. Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. Cell 2024.","DOI":"10.1016\/j.cell.2024.09.004"},{"key":"2024110512151066000_2024.10.29.620946v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2024.103169"},{"key":"2024110512151066000_2024.10.29.620946v1.9","doi-asserted-by":"crossref","unstructured":"Mullard A. In vivo CAR T cells move into clinical trials. Nature reviews Drug discovery 2024.","DOI":"10.1038\/d41573-024-00150-z"},{"key":"2024110512151066000_2024.10.29.620946v1.10","doi-asserted-by":"crossref","unstructured":"Xu EJK , Smith BE , Conce Alberto WD , Walsh MJ , Lim B , Hoffman MT , et al. Peptide-MHC-targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells. bioRxiv 2024: 2024.2009.2018.613594.","DOI":"10.1101\/2024.09.18.613594"},{"key":"2024110512151066000_2024.10.29.620946v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01328-9"},{"key":"2024110512151066000_2024.10.29.620946v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.09.014"},{"key":"2024110512151066000_2024.10.29.620946v1.13","unstructured":"Ascic E , \u00c5kerstr\u00f6m F , Sreekumar Nair M , Rosa A , Kurochkin I , Zimmermannova O , et al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science, 0(0): eadn9083."},{"key":"2024110512151066000_2024.10.29.620946v1.14","doi-asserted-by":"crossref","unstructured":"Nawaz W , Huang B , Xu S , Li Y , Zhu L , Wu Z , et al. AAV-Mediated In Vivo CAR Gene Therapy for Targeting Human T Cell Leukemia. bioRxiv 2021: 2021.2002.2015.431201.","DOI":"10.1101\/2021.02.15.431201"},{"key":"2024110512151066000_2024.10.29.620946v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-00756-9"},{"key":"2024110512151066000_2024.10.29.620946v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.01.001"},{"key":"2024110512151066000_2024.10.29.620946v1.17","doi-asserted-by":"publisher","DOI":"10.1039\/D3NA00198A"},{"key":"2024110512151066000_2024.10.29.620946v1.18","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202304378"},{"key":"2024110512151066000_2024.10.29.620946v1.19","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02566-0"},{"key":"2024110512151066000_2024.10.29.620946v1.20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050219-034237"},{"key":"2024110512151066000_2024.10.29.620946v1.21","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1991.18"},{"key":"2024110512151066000_2024.10.29.620946v1.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-204875"},{"key":"2024110512151066000_2024.10.29.620946v1.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116277119"},{"key":"2024110512151066000_2024.10.29.620946v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-022-01436-z"},{"key":"2024110512151066000_2024.10.29.620946v1.25","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202100034"},{"key":"2024110512151066000_2024.10.29.620946v1.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3354"},{"key":"2024110512151066000_2024.10.29.620946v1.27","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm7950"},{"key":"2024110512151066000_2024.10.29.620946v1.28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1377322"},{"key":"2024110512151066000_2024.10.29.620946v1.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08534-1"},{"key":"2024110512151066000_2024.10.29.620946v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.02.007"},{"key":"2024110512151066000_2024.10.29.620946v1.31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0932778100"},{"key":"2024110512151066000_2024.10.29.620946v1.32","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf4398"},{"key":"2024110512151066000_2024.10.29.620946v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.85"},{"key":"2024110512151066000_2024.10.29.620946v1.34","doi-asserted-by":"crossref","unstructured":"Goyette J , Nieves DJ , Ma Y , Gaus K. How does T cell receptor clustering impact on signal transduction? Journal of Cell Science 2019, 132(4).","DOI":"10.1242\/jcs.226423"},{"key":"2024110512151066000_2024.10.29.620946v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2008.09.014"},{"key":"2024110512151066000_2024.10.29.620946v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00985-4"},{"key":"2024110512151066000_2024.10.29.620946v1.37","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aai7793"},{"key":"2024110512151066000_2024.10.29.620946v1.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902226"},{"key":"2024110512151066000_2024.10.29.620946v1.39","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.6b01178"},{"key":"2024110512151066000_2024.10.29.620946v1.40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0030183"},{"key":"2024110512151066000_2024.10.29.620946v1.41","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.17.10107"},{"key":"2024110512151066000_2024.10.29.620946v1.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.1.123"},{"key":"2024110512151066000_2024.10.29.620946v1.43","doi-asserted-by":"crossref","unstructured":"Sims EK , Bundy BN , Stier K , Serti E , Lim N , Long SA , et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 2021, 13(583).","DOI":"10.1126\/scitranslmed.abc8980"},{"key":"2024110512151066000_2024.10.29.620946v1.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0427-6"},{"key":"2024110512151066000_2024.10.29.620946v1.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"2024110512151066000_2024.10.29.620946v1.46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1860"},{"key":"2024110512151066000_2024.10.29.620946v1.47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2138"},{"key":"2024110512151066000_2024.10.29.620946v1.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2920"},{"key":"2024110512151066000_2024.10.29.620946v1.49","doi-asserted-by":"crossref","unstructured":"Su F-Y , Zhao Q , Dahotre SN , Gamboa L , Bawage SS , Silva Trenkle AD , et al. In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles. bioRxiv 2021: 2021.2010.2014.464373.","DOI":"10.1101\/2021.10.14.464373"},{"key":"2024110512151066000_2024.10.29.620946v1.50","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0122"},{"key":"2024110512151066000_2024.10.29.620946v1.51","unstructured":"Zhou D , Sun Q , Xia J , Gu W , Qian J , Zhuang W , et al. Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. The Lancet Haematology."},{"key":"2024110512151066000_2024.10.29.620946v1.52","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0020"},{"key":"2024110512151066000_2024.10.29.620946v1.53","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00372-6"},{"key":"2024110512151066000_2024.10.29.620946v1.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"2024110512151066000_2024.10.29.620946v1.55","doi-asserted-by":"crossref","unstructured":"Smith EL , Harrington K , Staehr M , Masakayan R , Jones J , Long TJ , et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med 2019, 11(485).","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"2024110512151066000_2024.10.29.620946v1.56","unstructured":"Liu RJBLS . Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof. 2017."},{"key":"2024110512151066000_2024.10.29.620946v1.57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.609421"},{"key":"2024110512151066000_2024.10.29.620946v1.58","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01007-w"},{"key":"2024110512151066000_2024.10.29.620946v1.59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-028001"},{"key":"2024110512151066000_2024.10.29.620946v1.60","doi-asserted-by":"crossref","unstructured":"Goldberg SD , Felix N , McCauley M , Eberwine R , Casta L , Haskell K , et al. A Strategy for Selective Deletion of Autoimmunity-Related T Cells by pMHC-Targeted Delivery. Pharmaceutics 2021, 13(10).","DOI":"10.3390\/pharmaceutics13101669"},{"key":"2024110512151066000_2024.10.29.620946v1.61","doi-asserted-by":"crossref","unstructured":"Guo XJ , Elledge SJ. V-CARMA: A tool for the detection and modification of antigen-specific T cells. Proc Natl Acad Sci U S A 2022, 119(4).","DOI":"10.1073\/pnas.2116277119"},{"key":"2024110512151066000_2024.10.29.620946v1.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.12.007"},{"key":"2024110512151066000_2024.10.29.620946v1.63","doi-asserted-by":"crossref","unstructured":"Ayala Ceja M , Khericha M , Harris CM , Puig-Saus C , Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. The Journal of experimental medicine 2024, 221(2).","DOI":"10.1084\/jem.20230903"},{"key":"2024110512151066000_2024.10.29.620946v1.64","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594"},{"key":"2024110512151066000_2024.10.29.620946v1.65","first-page":"S25","volume":"17","author":"61. Effects of Chimeric Antigen Receptor (CAR) Expression on Regulatory T Cells","year":"2009","journal-title":"Molecular Therapy"},{"key":"2024110512151066000_2024.10.29.620946v1.66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1860"},{"key":"2024110512151066000_2024.10.29.620946v1.67","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.17.10107"},{"key":"2024110512151066000_2024.10.29.620946v1.68","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(99)01320-4"},{"key":"2024110512151066000_2024.10.29.620946v1.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.05.042"},{"key":"2024110512151066000_2024.10.29.620946v1.70","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-017-0043-5"},{"key":"2024110512151066000_2024.10.29.620946v1.71","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03862-z"},{"key":"2024110512151066000_2024.10.29.620946v1.72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36225-5"},{"key":"2024110512151066000_2024.10.29.620946v1.73","doi-asserted-by":"publisher","DOI":"10.2337\/db15-0449"},{"key":"2024110512151066000_2024.10.29.620946v1.74","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04248-x"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.10.29.620946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:22:40Z","timestamp":1768461760000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.10.29.620946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,3]]},"references-count":74,"URL":"https:\/\/doi.org\/10.1101\/2024.10.29.620946","relation":{},"subject":[],"published":{"date-parts":[[2024,11,3]]},"subtype":"preprint"}}